Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara A Blodi

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Retina (Philadelphia, Pa.)|October 7, 2010
Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor studySrinivas R Sadda, Glenn Stoller, David S Boyer, et al.
American Journal of Ophthalmology|December 30, 2022
SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness OutcomesIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Ophthalmology. Retina|April 22, 2023
Prevalence of Macular Atrophy in the MARINA Study of Ranibizumab versus Sham for Neovascular Age-Related Macular DegenerationBarbara A Blodi, Amitha Domalpally, Ellie Corkery, et al.
Plos One|February 26, 2024
Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patientsChristine M Sorenson, Zafer Gurel, Yong-Seok Song, et al.
American Journal of Ophthalmology|July 25, 2016
SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein OcclusionIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
Retina (Philadelphia, Pa.)|May 11, 2018
LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALSJan S Peterson, Kenneth Rockwell, Ingrid U Scott, et al.
American Journal of Ophthalmology|July 9, 2010
The prevalence of macular telangiectasia type 2 in the Beaver Dam eye studyRonald Klein, Barbara A Blodi, Stacy M Meuer, et al.
American Journal of Ophthalmology|August 14, 2009
SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe designIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|January 8, 2021
Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trialRahul N Khurana, Neal L Oden, Paul C VanVeldhuisen, et al.
JAMA Ophthalmology|June 19, 2015
Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15Ahmad A Aref, Ingrid U Scott, Neal L Oden, et al.
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Retina (Philadelphia, Pa.)|October 7, 2010
Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor studySrinivas R Sadda, Glenn Stoller, David S Boyer, et al.
American Journal of Ophthalmology|December 30, 2022
SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness OutcomesIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Ophthalmology. Retina|April 22, 2023
Prevalence of Macular Atrophy in the MARINA Study of Ranibizumab versus Sham for Neovascular Age-Related Macular DegenerationBarbara A Blodi, Amitha Domalpally, Ellie Corkery, et al.
Plos One|February 26, 2024
Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patientsChristine M Sorenson, Zafer Gurel, Yong-Seok Song, et al.
American Journal of Ophthalmology|July 25, 2016
SCORE2 Report 1: Techniques to Optimize Recruitment in Phase III Clinical Trials of Patients With Central Retinal Vein OcclusionIngrid U Scott, Paul C VanVeldhuisen, Michael S Ip, et al.
Retina (Philadelphia, Pa.)|May 11, 2018
LONG-TERM PHYSICAL STABILITY, STERILITY, AND ANTI-VEGF BIOACTIVITY OF REPACKAGED BEVACIZUMAB IN 2-ML GLASS VIALSJan S Peterson, Kenneth Rockwell, Ingrid U Scott, et al.
American Journal of Ophthalmology|July 9, 2010
The prevalence of macular telangiectasia type 2 in the Beaver Dam eye studyRonald Klein, Barbara A Blodi, Stacy M Meuer, et al.
American Journal of Ophthalmology|August 14, 2009
SCORE Study Report 7: incidence of intravitreal silicone oil droplets associated with staked-on vs luer cone syringe designIngrid U Scott, Neal L Oden, Paul C VanVeldhuisen, et al.
Graefe'S Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie|January 8, 2021
Association between early and late response in eyes with central or hemiretinal vein occlusion treated with anti-VEGF agents : SCORE2 report 12: secondary analysis of the SCORE2 clinical trialRahul N Khurana, Neal L Oden, Paul C VanVeldhuisen, et al.
JAMA Ophthalmology|June 19, 2015
Incidence, Risk Factors, and Timing of Elevated Intraocular Pressure After Intravitreal Triamcinolone Acetonide Injection for Macular Edema Secondary to Retinal Vein Occlusion: SCORE Study Report 15Ahmad A Aref, Ingrid U Scott, Neal L Oden, et al.
Pageof 9